Arcturus Net Tangible Assets vs Property Plant Equipment Analysis

ARCT Stock

USD 26.55 0.38 1.45%

Arcturus Therapeutics financial indicator trend analysis is way more than just evaluating Arcturus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcturus Therapeutics is a good investment. Please check the relationship between Arcturus Therapeutics Net Tangible Assets and its Property Plant Equipment accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Net Tangible Assets vs Property Plant Equipment

Net Tangible Assets vs Property Plant Equipment Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcturus Therapeutics Net Tangible Assets account and Property Plant Equipment. At this time, the significance of the direction appears to have strong relationship.

The correlation between Arcturus Therapeutics' Net Tangible Assets and Property Plant Equipment is 0.63. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Arcturus Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Arcturus Therapeutics' Net Tangible Assets and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Arcturus Therapeutics Holdings are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Net Tangible Assets i.e., Arcturus Therapeutics' Net Tangible Assets and Property Plant Equipment go up and down completely randomly.

Correlation Coefficient

0.63

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Property Plant Equipment

Most indicators from Arcturus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcturus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

At this time, Arcturus Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 578.5 K in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.2M	1.5M	2.7M	2.8M
Interest Income	753K	2.6M	12.3M	12.9M

Reconciled Depreciation Interest Income

Arcturus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Short Term Debt	Net Tangible Assets	Other Assets	Inventory
Total Assets		0.97	0.92	0.98	0.82	-0.98	-0.91	0.84	0.99	0.79	0.59	0.99	0.61	-0.25	0.95	0.9	0.99	0.92	0.81	1.0	-0.24	0.76	0.55	0.95	0.9	-0.05
Other Current Liab	0.97		0.98	0.9	0.9	-0.91	-0.97	0.78	0.95	0.87	0.63	0.95	0.64	-0.23	0.98	0.97	0.98	0.98	0.88	0.95	-0.22	0.87	0.67	0.85	0.77	-0.05
Total Current Liabilities	0.92	0.98		0.83	0.88	-0.86	-0.95	0.78	0.91	0.84	0.6	0.9	0.54	-0.22	0.95	0.95	0.93	0.99	0.84	0.91	-0.22	0.94	0.77	0.78	0.68	-0.02
Total Stockholder Equity	0.98	0.9	0.83		0.74	-0.99	-0.82	0.81	0.98	0.72	0.51	0.98	0.56	-0.25	0.88	0.82	0.95	0.83	0.73	0.98	-0.24	0.65	0.45	0.98	0.96	-0.06
Property Plant And Equipment Net	0.82	0.9	0.88	0.74		-0.73	-0.89	0.5	0.77	0.96	0.57	0.76	0.78	-0.23	0.86	0.96	0.86	0.89	0.99	0.79	-0.23	0.74	0.6	0.68	0.56	-0.04
Net Debt	-0.98	-0.91	-0.86	-0.99	-0.73		0.83	-0.88	-0.99	-0.69	-0.55	-0.99	-0.53	0.26	-0.91	-0.81	-0.95	-0.86	-0.71	-0.99	0.25	-0.7	-0.48	-0.98	-0.96	0.03
Retained Earnings	-0.91	-0.97	-0.95	-0.82	-0.89	0.83		-0.68	-0.87	-0.87	-0.75	-0.87	-0.7	0.24	-0.95	-0.97	-0.96	-0.97	-0.88	-0.89	0.23	-0.82	-0.59	-0.76	-0.65	0.12
Accounts Payable	0.84	0.78	0.78	0.81	0.5	-0.88	-0.68		0.88	0.45	0.38	0.87	0.22	-0.17	0.83	0.61	0.77	0.78	0.46	0.85	-0.16	0.75	0.51	0.8	0.83	0.03
Cash	0.99	0.95	0.91	0.98	0.77	-0.99	-0.87	0.88		0.73	0.57	1.0	0.54	-0.26	0.94	0.86	0.96	0.91	0.75	1.0	-0.26	0.77	0.55	0.96	0.93	-0.04
Non Current Assets Total	0.79	0.87	0.84	0.72	0.96	-0.69	-0.87	0.45	0.73		0.55	0.73	0.75	-0.21	0.82	0.96	0.84	0.85	0.96	0.76	-0.21	0.7	0.59	0.66	0.52	-0.07
Non Currrent Assets Other	0.59	0.63	0.6	0.51	0.57	-0.55	-0.75	0.38	0.57	0.55		0.55	0.76	-0.25	0.67	0.64	0.67	0.68	0.62	0.58	-0.25	0.42	0.07	0.54	0.4	-0.05
Cash And Short Term Investments	0.99	0.95	0.9	0.98	0.76	-0.99	-0.87	0.87	1.0	0.73	0.55		0.53	-0.25	0.93	0.86	0.97	0.9	0.74	1.0	-0.24	0.76	0.55	0.96	0.93	-0.04
Net Receivables	0.61	0.64	0.54	0.56	0.78	-0.53	-0.7	0.22	0.54	0.75	0.76	0.53		-0.11	0.66	0.71	0.68	0.63	0.84	0.58	-0.11	0.26	-0.01	0.54	0.42	-0.04
Common Stock Total Equity	-0.25	-0.23	-0.22	-0.25	-0.23	0.26	0.24	-0.17	-0.26	-0.21	-0.25	-0.25	-0.11		-0.19	-0.23	-0.26	-0.21	-0.23	-0.24	1.0	-0.17	-0.17	-0.32	-0.25	0.58
Common Stock Shares Outstanding	0.95	0.98	0.95	0.88	0.86	-0.91	-0.95	0.83	0.94	0.82	0.67	0.93	0.66	-0.19		0.92	0.96	0.98	0.85	0.95	-0.19	0.83	0.58	0.84	0.77	-0.07
Other Current Assets	0.9	0.97	0.95	0.82	0.96	-0.81	-0.97	0.61	0.86	0.96	0.64	0.86	0.71	-0.23	0.92		0.94	0.95	0.95	0.88	-0.22	0.82	0.66	0.76	0.64	-0.08
Other Stockholder Equity	0.99	0.98	0.93	0.95	0.86	-0.95	-0.96	0.77	0.96	0.84	0.67	0.97	0.68	-0.26	0.96	0.94		0.94	0.85	0.98	-0.25	0.77	0.54	0.91	0.84	-0.1
Total Liab	0.92	0.98	0.99	0.83	0.89	-0.86	-0.97	0.78	0.91	0.85	0.68	0.9	0.63	-0.21	0.98	0.95	0.94		0.87	0.91	-0.21	0.9	0.67	0.79	0.69	-0.01
Property Plant And Equipment Gross	0.81	0.88	0.84	0.73	0.99	-0.71	-0.88	0.46	0.75	0.96	0.62	0.74	0.84	-0.23	0.85	0.95	0.85	0.87		0.77	-0.22	0.67	0.52	0.68	0.55	-0.04
Total Current Assets	1.0	0.95	0.91	0.98	0.79	-0.99	-0.89	0.85	1.0	0.76	0.58	1.0	0.58	-0.24	0.95	0.88	0.98	0.91	0.77		-0.24	0.75	0.53	0.96	0.92	-0.04
Common Stock	-0.24	-0.22	-0.22	-0.24	-0.23	0.25	0.23	-0.16	-0.26	-0.21	-0.25	-0.24	-0.11	1.0	-0.19	-0.22	-0.25	-0.21	-0.22	-0.24		-0.16	-0.16	-0.32	-0.25	0.58
Short Long Term Debt Total	0.76	0.87	0.94	0.65	0.74	-0.7	-0.82	0.75	0.77	0.7	0.42	0.76	0.26	-0.17	0.83	0.82	0.77	0.9	0.67	0.75	-0.16		0.9	0.6	0.5	0.03
Short Term Debt	0.55	0.67	0.77	0.45	0.6	-0.48	-0.59	0.51	0.55	0.59	0.07	0.55	-0.01	-0.17	0.58	0.66	0.54	0.67	0.52	0.53	-0.16	0.9		0.39	0.31	-0.03
Net Tangible Assets	0.95	0.85	0.78	0.98	0.68	-0.98	-0.76	0.8	0.96	0.66	0.54	0.96	0.54	-0.32	0.84	0.76	0.91	0.79	0.68	0.96	-0.32	0.6	0.39		0.97	-0.04
Other Assets	0.9	0.77	0.68	0.96	0.56	-0.96	-0.65	0.83	0.93	0.52	0.4	0.93	0.42	-0.25	0.77	0.64	0.84	0.69	0.55	0.92	-0.25	0.5	0.31	0.97		-0.05
Inventory	-0.05	-0.05	-0.02	-0.06	-0.04	0.03	0.12	0.03	-0.04	-0.07	-0.05	-0.04	-0.04	0.58	-0.07	-0.08	-0.1	-0.01	-0.04	-0.04	0.58	0.03	-0.03	-0.04	-0.05

Click cells to compare fundamentals

Arcturus Therapeutics Account Relationship Matchups

Arcturus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	82.1M	476.5M	392.8M	450.4M	429.4M	450.9M
Other Current Liab	6.3M	17.8M	23.5M	30.2M	25.1M	26.3M
Total Current Liabilities	21.3M	49.5M	99.5M	127.0M	82.0M	86.1M
Total Stockholder Equity	25.8M	396.6M	228.2M	270.3M	278.5M	292.4M
Property Plant And Equipment Net	7.5M	8.6M	11.3M	45.0M	40.9M	43.0M
Net Debt	(51.5M)	(445.0M)	(302.9M)	(301.0M)	(316.8M)	(300.9M)
Retained Earnings	(71.7M)	(143.8M)	(347.5M)	(338.1M)	(367.9M)	(349.5M)
Accounts Payable	5.8M	10.8M	10.1M	7.4M	5.3M	3.8M
Cash	71.4M	462.9M	370.5M	391.9M	347.0M	364.4M
Non Current Assets Total	7.9M	8.7M	13.9M	47.1M	42.8M	45.0M
Cash And Short Term Investments	71.4M	462.9M	370.5M	391.9M	347.0M	364.4M
Net Receivables	2.2M	2.1M	3.4M	2.8M	32.1M	33.7M
Common Stock Total Equity	212K	214K	15K	26K	29.9K	28.4K
Common Stock Shares Outstanding	12.1M	20.3M	26.3M	27.1M	26.6M	28.0M
Liabilities And Stockholders Equity	82.1M	476.5M	392.8M	450.4M	429.4M	450.9M
Other Current Assets	758K	2.8M	5.1M	8.7M	7.5M	7.9M
Other Stockholder Equity	97.4M	540.3M	575.7M	608.4M	646.4M	678.7M
Total Liab	56.4M	79.9M	164.6M	180.1M	150.9M	158.4M
Property Plant And Equipment Gross	7.5M	8.6M	11.3M	45.0M	49.7M	52.2M
Total Current Assets	74.3M	467.8M	379.0M	403.3M	386.6M	405.9M
Common Stock	214K	15K	26K	27K	31.1K	29.5K
Short Long Term Debt Total	19.8M	17.9M	67.6M	90.9M	30.2M	32.6M
Net Tangible Assets	13.6M	25.8M	396.6M	228.2M	262.4M	275.6M
Property Plant Equipment	7.5M	3.4M	11.3M	45.0M	51.7M	54.3M
Capital Surpluse	58.3M	97.4M	540.3M	575.7M	662.0M	695.1M
Other Liab	15.2M	12.5M	19.9M	22.9M	26.3M	14.0M
Non Current Liabilities Total	35.0M	30.4M	65.1M	53.1M	68.9M	38.2M
Current Deferred Revenue	8.4M	18.1M	43.5M	28.6M	47.3M	24.9M
Net Invested Capital	40.8M	411.6M	291.3M	331.0M	278.5M	221.7M
Net Working Capital	53.0M	418.3M	279.4M	276.3M	304.6M	220.1M

Pair Trading with Arcturus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcturus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcturus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Arcturus Stock

0.78	ACB	Aurora Cannabis Sell-off Trend	Pair Corr
0.75	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr
0.63	ELYM	Eliem Therapeutics Upward Rally	Pair Corr

The ability to find closely correlated positions to Arcturus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcturus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcturus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcturus Therapeutics Holdings to buy it.

The correlation of Arcturus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcturus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcturus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arcturus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Arcturus Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Arcturus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Arcturus Therapeutics Holdings Stock. Highlighted below are key reports to facilitate an investment decision about Arcturus Therapeutics Holdings Stock:

How To Invest In Arcturus

Details

Is Arcturus Stock a good investment?

Details

What is Arcturus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Note that the Arcturus Therapeutics information on this page should be used as a complementary analysis to other Arcturus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Arcturus Stock analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Transaction History View history of all your transactions and understand their impact on performance
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets

Is Arcturus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.12)

Revenue Per Share

6.264

Quarterly Revenue Growth

(0.81)

Return On Assets

(0.11)

Return On Equity

(0.11)

The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arcturus Net Tangible Assets vs Property Plant Equipment Analysis

Net Tangible Assets vs Property Plant Equipment

Net Tangible Assets vs Property Plant Equipment Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Property Plant Equipment

Arcturus Therapeutics fundamental ratios Correlations

Arcturus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arcturus Therapeutics fundamental ratios Accounts

Pair Trading with Arcturus Therapeutics

Moving against Arcturus Stock

Complementary Tools for Arcturus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash	+ 0.99	Total Assets

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Tangible Assets	- 0.98	Net Debt
Net Debt	- 0.98	Total Assets